Page Title

SARS-CoV-2 study kicks off in Germany

Vakzine Projekt Management GmbH (VPM) announced that the first participant has been enrolled on May 25th in a phase III study to investigate whether the vaccine candidate VPM1002 is effective against respiratory disease like COVID-19 The large-scale study is initially to be carried out at several hospitals in Hanover, Munich, Erfurt and will soon include additional cities. The clinical trial will include healthcare workers which are particularly at risk from the disease. More!